Non human primate models for Alzheimer's disease-related research and drug discovery.

  title={Non human primate models for Alzheimer's disease-related research and drug discovery.},
  author={Debby Van Dam and Peter Paul De Deyn},
  journal={Expert Opinion on Drug Discovery},
  • D. V. Dam, P. Deyn
  • Published 1 February 2017
  • Biology
  • Expert Opinion on Drug Discovery
ABSTRACTIntroduction: Pathophysiological mechanisms underlying Alzheimer’s disease (AD) remain insufficiently documented for the identification of accurate diagnostic markers and purposeful target discovery and development. Nonhuman primates (NHPs) have important translational value given their close phylogenetic relationship to humans and similar developmental paths in (neuro)anatomy, physiology, genetics, and neural functions, as well as cognition, emotion, and social behavior.Areas covered… 

Rodent models for Alzheimer disease

This Review critically evaluates the genetic and non-genetic strategies used in AD modelling, discussing their strengths and limitations, as well as new opportunities for the development of better models for the disease.

Welcome note for special issue “Clinical Diagnosis of Alzheimer’s disease”

This work invites submissions of original studies, reviews, case reports or other types of scientific work related but not entirely limited to the following topics: development and application of brain imaging technologies, CSF/peripheral biomarkers and cognitive assessment battery for AD/dementia diagnosis.

Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer’s disease model mice and macaques

N neuritic plaques seen in transgenic AD model mouse brains represent an incomplete form of this AD pathological hallmark, and indicates more complex secondary proteopathies in the human brain relative to rodents and nonhuman primates during aging and in AD.

Aging‐related Alzheimer's disease‐like neuropathology and functional decline in captive vervet monkeys (Chlorocebus aethiops sabaeus)

The evidence supporting the vervet monkey as a model of aging-related AD-like neuropathology and associated phenotypes including cognitive function, physical function, glucose handling, intestinal physiology, and CSF, blood, and neuroimaging biomarkers is outlined.

Ethical issues when modelling brain disorders innon-human primates

  • C. Neuhaus
  • Biology, Psychology
    Journal of Medical Ethics
  • 2017
The paper concludes that it cannot be argued that animal welfare concerns, the availability of alternative methods of studying brain disorders, and unmet expectations of benefit justify a stop on the creation of NHP model organisms to study brain disorders.

Immunotherapy to improve cognition and reduce pathological species in an Alzheimer’s disease mouse model

This study shows that acute treatment with an aβComAb can effectively improve performance in behavioral testing without reduction of amyloid plaque burden, and that peripherally administered IgG can affect levels of pathological species in the brain.

Comparison of cerebrospinal fluid biomarkers relevant to neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys

Normative values for key neurodegeneration biomarkers were established for laboratory housed cynomolgus and rhesus macaque monkeys and differences were observed as a function of species, sex and site of CSF acquisition that should be considered when employing primate models.

Critical role of mitosis in spontaneous late-onset Alzheimer’s disease; from a Shugoshin 1 cohesinopathy mouse model

The Sgo1 model, the current “three-hit hypothesis” regarding LOAD development with an emphasis on critical role of prolonged mitosis in amyloid-beta accumulation, and implications for human LOAD intervention and treatment are discussed.

Human Brain Slice Culture: A Useful Tool to Study Brain Disorders and Potential Therapeutic Compounds

Human brain slices can provide a close representation of neuronal networks in vivo, be a valuable tool for investigation of the basis of neuropsychiatric disorders, and provide a platform for the evaluation of novel pharmacological treatments of human brain diseases.



Nonhuman primate models of Alzheimer-like cerebral proteopathy.

The resistance of monkeys and apes to tauopathy and AD-related neurodegeneration, in the presence of substantial cerebral Aβ deposition, suggests that a comparative analysis of human and nonhuman primates could yield informative clues to the uniquely human predisposition to Alzheimer's disease.

Current and Emerging Drug Treatment Options for Alzheimer’s Disease

A systematic review critically examines the efficacy and safety data for currently approved drugs and emerging treatments in AD, as well as discussing the present and future directions of innovation in this field.

Neurobiological Studies of Transmitter Systems in Aging and in Alzheimer‐Type Dementia a

Demonstration of the efficacy of new pharmacotherapies, neural grafts, and trophic factors designed to alleviate the effects of aging and disease on the human brain in nonhuman primates would have profound implications on the development of new therapies.

Transgenic mouse models of Alzheimer's disease: phenotype and application

How the availability of transgenic mouse models of AD should assist in the understanding of AD aetiology and the identification of effective treatments for this disease is described, and the role behavioural testing may have in future AD drug discovery research is considered.

Towards a transgenic model of Huntington’s disease in a non-human primate

Hallmark features of HD, including nuclear inclusions and neuropil aggregates, were observed in the brains of the HD transgenic monkeys, and the data suggest that it will be feasible to generate valuable non-human primate models of HD and possibly other human genetic diseases.

Genetically modified pig models for neurodegenerative disorders

A neuroanatomical overview in pigs is provided and a multiplex genome editing and preterm recloning approach is proposed by using the rapid growth of the ground‐breaking precision genome editing technology CRISPR/Cas9 and somatic cell nuclear transfer (SCNT) to shorten the temporal requirement in generating multiple transgenic pigs.

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

PET and SPECT have the ability to provide biomarkers that permit spatial assessment of pathophysiological molecular changes and therefore objectively evaluate and follow up therapeutic response, especially in the brain.

Natural Non-Trasgenic Animal Models for Research in Alzheimer’s Disease

The chick embryo and the dog may be better experimental models because their enzymatic machinery for processing APP is almost identical to that of humans, and could also serve as assay systems for Aβ-targeted drugs or new therapeutic strategies against this devastating disease.